| 前收盘价格 | 26.89 |
| 收盘价格 | 26.55 |
| 成交量 | 2,975,655 |
| 平均成交量 (3个月) | 9,495,053 |
| 市值 | 10,190,005,248 |
| 价格/销量 (P/S) | 3.55 |
| 股市价格/股市净资产 (P/B) | 1.16 |
| 52周波幅 | |
| 利润日期 | 1 Aug 2025 |
| 营业毛利率 | -105.67% |
| 营业利益率 (TTM) | -972.22% |
| 稀释每股收益 (EPS TTM) | -8.73 |
| 季度收入增长率 (YOY) | -35.30% |
| 总债务/股东权益 (D/E MRQ) | 7.40% |
| 流动比率 (MRQ) | 4.22 |
| 营业现金流 (OCF TTM) | -3.05 B |
| 杠杆自由现金流 (LFCF TTM) | -3.20 B |
| 资产报酬率 (ROA TTM) | -15.84% |
| 股东权益报酬率 (ROE TTM) | -29.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | Moderna, Inc. | 看跌 | 看跌 |
AIStockmoo 评分
-1.8
| 分析师共识 | -3.5 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.75 |
|
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 7.28% |
| 机构持股比例 | 73.67% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Theleme Partners Llp | 30 Jun 2025 | 7,868,810 |
| Flagship Pioneering Inc. | 30 Jun 2025 | 4,632,149 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 31.00 (Barclays, 18.37%) | 保留 |
| 中 | 26.00 (-0.73%) | |
| 低 | 25.00 (B of A Securities, -4.54%) | 卖出 |
| 平均值 | 27.33 (4.35%) | |
| 总计 | 1 保留, 2 卖出 | |
| 平均价格@调整类型 | 29.03 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Barclays | 04 Aug 2025 | 31.00 (18.37%) | 保留 | 27.64 |
| B of A Securities | 22 Jul 2025 | 25.00 (-4.54%) | 卖出 | 32.73 |
| JP Morgan | 22 May 2025 | 26.00 (-0.73%) | 卖出 | 26.72 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合